Search Results

1 - 10 of 219 items :

  • "cell transplantation" x
Clear All
Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients

. Chanock SJ, Walsh TJ. Invasive aspergillosis in bone marrow recipients. Bone Marrow Transplant. 1996;18 Suppl 3:S15-20. PMID: 8971401 Marr KA. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917. doi:10.1086/339202 PMID:11880955 Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F. Candidemia in cancer patients: a prospective, multicenter surveillance study by the

Open access
Autologous Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: a Single-Centre Experience

References 1. Apperley J, Carreras E, Gluckman E, Masszi T. The EBMT Handbook Haematopoietic Stem Cell Transplantation. 6th Revised Edition. 2012:317-326 2. Tsimberidou AM, Stavroyianni N, Viniou N. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003;97(7):1721-1731. 3. Büchner T, Berdel WE, Schoch C, et al. Double induction containing

Open access
Posterior Reversible Encephalopathy Syndrome (PRES) in Children Undergoing Allogeneic Stem Cell Transplantation

.1542/peds.2014-2325 3. D Zama, R Masetti, DM Cordelli, et all. Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplantation (2014) 49, 1538–1540 4. Javid Gaziev, Simone Marziali, Katia Paciaroni et all. Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies. Biology of Blood and Marrow Transplantation Journal, 2017. 23:9;1531-1540. doi: 10.1016/j. bbmt.2017.05.033. 5. K Straathof, P Anoop, Z Allwood, J

Open access
The Importance of Positive Immunomagnetic Cell Separation Prior to Autologous Hematopoetic Stem Cell Transplantation for Advanced Stage Lymphomas

and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015;7:280rv2. 5. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasm. Blood. 2008;111:3941-3967. 6. Padmanee Sharma, James P. Allison, Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell Press. 2015;161:205-214. 7. Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M, Van Badiavas E. Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and

Open access
First Successful Haploidentical Stem Cell Transplantation in Romania

References 1. GYURKOCZA B., REZVANI A., STORB RF. Allogeneic hematopoietic cell transplantation: the state-of-the-art. Expert Rev Hematol. 2010; 3(3):285-99. 2. BARON F., STORB R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol. 2004; 26(1-2):71-94. 3. BARONF., STORB R., LITTLE MT. Hematopoietic cell transplantation: five decades of progress. Arch Med Res. 2003; 34(6):528-44. 4. STAAL F.J., BAUM C

Open access
Unrelated Allogeneic Stem Cell Transplantation in a Patient with Chronic Myeloid Leukemia in Blast Crisis

. Karbasian Esfahani M, Morris EL, Dutcher JP, et al. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol . 2006;7:189-199. 6. Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood . 2011;117:755-763. 7. Tunyogi AB, Benedek I, Benedek Lázár E, et al. The results of allogeneic stem cell transplantation in CML – the experience of BMT Unit Tîrgu Mureş. Acta Medica Marisiensis . 2011;57:371-374. 8. Gupta A, Khattry N. Current status of hematopoietic stem

Open access
Post Autologous Stem Cell Transplantation Complication Management in Case of Malignant Lymphoma Patients

REFERENCES 1. Hübel K, de la Rubbia J, Azar N, et al. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. Eur J Haematol . 2015;94:12-22. 2. Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol . 2017;29:455-459. 3. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04

Open access
Kidney Complications Due to Hematopoietic Stem Cell Transplantation-A Disorder of an Increasing Incidence?

References 1. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J2011; 1:e16; doi:10.1038/bcj.2011.14; published online 29 April 2011. 2. Singh N, McNeely J, Parikh S, et al . Kidney complications of hematopoietic stem cell transplantation. Am J Kidney Dis 2013; 61: 809-821. 3. Martin PJ, Counts Jr GW, Appelbaum FR, et al . Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011

Open access
The Evolution of Intracardiac Hemodynamics Post Autologous Stem Cell Transplant in a Case of Multiple Myeloma Associated with Severe Tricuspid and Mitral Valve Insufficiency

to the Durie Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia . 2009;23:1528-1534. 6. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol . 2005;23:3412-3420. 7. San Miguel JF, Bladé Creixenti J, García-Sanz R. Treatment of multiple myeloma. Haematologica . 1999;84:36-58. 8. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue

Open access
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Introduction Novel agents have significantly increased the response rate and overall survival (OS) of patients with multiple myeloma (MM), but high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are still considered the standard of care for younger patients. 1 - 5 Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. Considering growth factors, the most commonly used are filgrastim (G-CSF) and the long acting pegfilgrastim. 6 - 8 The combination of

Open access